Global Cancer Technology

Global Cancer Technology is developing a remote-controlled drug-delivery platform for cancer treatments.

The key to this platform is its ability to keep a drug “inactive” until it reaches the site of a tumor. Once there, the drug is activated through a micro-dose of radiation, and can attack the tumor while keeping healthy tissue and cells unharmed.

Global Cancer Technology is led by CEO John Clark, a 25-year veteran of the medical industry. Supporting him are advisors with extensive experience in neurosurgery, cancer-related nanotechnology, and medical product commercialization.

Through a partnership with the Moores Cancer Center at UC San Diego — a top 20 hospital in the world for clinical medicine — this company has secured the exclusive license to this platform’s patented technology.

In 2021, Global Cancer Technology received approval to begin animal testing in pre-clinical trials. Now it’s seeking capital to begin Phase 1 clinical trials — slated for summer 2022 — with plans to bring its platform to market by 2025.

Global Cancer Technology’s platform is what’s referred to as a Novel Drug-Delivery System, or “NDDS.” This refers to new approaches, technologies, and systems for transporting medicine into the body.

Unlike conventional systems, NDDS combine advanced techniques with superior dosing regimens. According to Kenneth Research, a market research company, the global market for NDDS is projected to reach $320 billion by 2021.

Global Cancer Technology’s system is designed to target one of the world’s leading causes of death: cancer.

In 2019, 1.7 million Americans were diagnosed with cancer. More than 600,000 of them will die from it. According to the American Cancer Society, men and women have around a 40% chance of developing cancer in their lifetime.

Current treatment options aren’t effective, and can cause harmful side effects.

Chemotherapy, for example, attempts to eliminate cancer cells throughout a patient’s entire body. But chemo drugs can’t tell the difference between cancerous cells and healthy cells. As a result, it kills them both.

This creates debilitating side effects.

Global Cancer Technology’s drug delivery platform reduces these side effects by ensuring that cancer treatments target only the tumor. Here’s how:

The company has created a nanoparticle that attaches to a cancer-fighting drug. More specifically, cancer drug molecules are linked to Scintillating NanoCrystals, which act as the delivery vehicle and can travel throughout the body easily. This linking process is part of the patented technology Global Cancer Technology has licensed.

Because they’re linked, the cancer drug molecules are “inactive.” When the nanoparticle reaches the tumor, the Scintillating NanoCrystals are exposed to a low dose of radiation. They then “light up,” breaking the links that bind them to the cancer drug.

As a result, the previously inactive drug molecules are activated at the site of the tumor. And because the level of radiation is so low, the damage sustained to the body is significantly less compared to traditional high-dose regimens.

Global Cancer Technology has gathered pre-clinical data on its platform, and engaged in advanced conversations with companies that have proven track records in drug-delivery development. These include NantHealth (Nasdaq: NH), a company developing and marketing healthcare solutions.

NantHealth’s investors include Celgene, a biotech company with $15 billion in annual revenues, and Allscripts Healthcare Solutions (Nasdaq: MDRX).

Once on the market, Global Cancer Technology’s platform could be leveraged by leading pharmaceutical companies, such as Novartis (NYSE: NVS), Johnson & Johnson (NYSE: JNJ), Sanofi (Nasdaq: SNY), or Eli Lilly (NYSE: LLY).

Team Background

Karen Newell-Rogers - Chief Scientific Officer

Karen is a microbiologist with expertise in immune response genetics. Several commercialized technologies have resulted from her research.

Primarily, she has spent time in academia, serving as a professor at the University of Vermont, University of Colorado, Colorado Springs, and Texas A&M University.

She was also Chief Scientific Officer with a pair of biotech companies, Aspire Biotech and BCell Solutions.

Karen holds a Bachelor’s degree in Microbiology and Immunology from the University of Texas at Austin, and a Ph.D. from the University of Colorado.

John Clark - Chief Executive Officer

John Clark has more than 25 years of experience in the medical industry.

He was Founder and CEO of American Radiosurgery, a San Diego-based company providing surgeons with neurosurgical equipment. This was the first company in the U.S. to create a device for the use of rotating gamma technology, a surgical technique that enables doctors to more precisely treat brain tumors.

Prior to that, he was a financial partner at Endolase, a medical company focused on creating surgical lasers used in cataract surgery procedures.

John studied at the University of Scranton.

Peter Hanson - Chief Financial Officer

Peter has 30 years of financial experience, having served as a principal or Chief Financial Officer at multiple financial firms.

He began his career in public accounting and became a partner with Arthur Young & Company, the predecessor of Ernst & Young.

After that, he was CFO of NuCorp Energy and Mitchell International, a software company. He was then principal of Polaris Capital, an investment banking firm.

Marc Potvin - President

Marc has more than 25 years of experience in operations, sales, and strategy in the medical device space.

Prior to joining Global Cancer Technology, he was President of CallCancerMD, a company providing telehealth services to patients in Canada.

In addition to his experience in the medical industry, he was Vice President of Acquisition with Lotus Equity Partners, a company acquiring and developing commercial real estate. Prior to that, he was Managing Partner of Agility Management Group, a Human Resources firm supporting startups and Fortune 1000 companies.

Marc earned a Bachelor’s degree in Marketing from McGill University.

Co-Investors